Meloxicam is a Small Molecule owned by Baudax Bio, and is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned.

Meloxicam is an NSAID (nonsteroidal anti-inflammatory drug) that works by inhibiting the action of certain enzymes cycloxygenase 1 and cycloxygenase 2 which makes hormones that cause pain in the body. These hormones are called prostaglandins. By blocking the effects of prostaglandins, meloxicam can help alleviate pain.

The revenue for Meloxicam is expected to reach a total of $3.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Meloxicam NPV Report.

Meloxicam is currently owned by Baudax Bio.

Meloxicam Overview

Meloxicam (Anjeso) is an oxicam derivative belongs to non steroidal anti-inflammatory drug (NSAID). It is formulated as solution for intravenous route of administration. Anjeso is indicated for the treatment of moderate-to-severe pain, alone or in combination with non-NSAID analgesics in adults

Meloxicam (N-1539) is under development for the treatment of acute pain in other global regions. The drug candidate is administered through intravenous and intramuscular routes. Meloxicam blocks the enzymes(COX-1, COX- 2) that make prostaglandins and reduces the levels of prostaglandins. It was also under development for the treatment of acute postoperative pain after open abdominal hysterectomy, hallux valgus deformity (Bunion), abdominal laparoscopic surgery and pain secondary to dental impaction surgery.

Baudax Bio Overview

Baudax Bio develops and commercializes novel products for acute care settings. The company’s lead product candidate meloxicam, an injection to treat osteoarthritis and rheumatoid arthritis. Baudax Bio is headquartered in Chester County, Pennsylvania, the US.

The company reported revenues of (US Dollars) US$1.1 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$0.5 million in FY2020. The operating loss of the company was US$19 million in FY2021, compared to an operating loss of US$74.8 million in FY2020. The net loss of the company was US$19.8 million in FY2021, compared to a net loss of US$76.1 million in FY2020. The company reported revenues of US$0.2 million for the third quarter ended September 2022, a decrease of 20.7% over the previous quarter.

Quick View – Meloxicam

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Meloxicam
Administration Pathway
  • Intramuscular
  • Intravenous
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.